Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Briney, Bryan S ^a   Willis, Jordan R ^b   Crowe, James E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LONG CHAIN HEAVY COMPLEMENTARITY DETERMINING REGION 3 ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CONTROLLED STUDY; D2 GENE; D3 GENE; GENE; GENE DELETION; GENE INSERTION; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; J GENE; MEMORY CELL; MULTIGENE FAMILY; NONHUMAN; POINT MUTATION; SOMATIC HYPERMUTATION; BLOOD; CLINICAL TRIAL; COMPLEMENTARITY DETERMINING REGION; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN STRUCTURE; MALE;

SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

COMPLEMENTARITY DETERMINING REGIONS; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN JOINING REGION; MALE; RECOMBINATION, GENETIC; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84860706280     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036750     Document Type: Article

References (52)

1. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, et al. (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279: 1256-1261 doi:10.1074/jbc.M307341200.
2. Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, et al. (2007) Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 15: 1452-1466 doi:10.1016/j.str.2007.09.011.
3. Burton DR, Stanfield RL, Wilson IA, (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102: 14943-14948 doi:10.1073/pnas.0505126102.
4. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289 doi:10.1126/science.1178746.
5. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110 doi:10.1128/JVI.00966-10.
6. Doores KJ, Burton DR, (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510-10521 doi:10.1128/JVI.00552-10.
7. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, et al. (2010) Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 107: 11483-11488 doi:10.1073/pnas.1004600107.
8. Changela A, Wu X, Yang Y, Zhang B, Zhu J, et al. (2011) Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 85: 2524-2535 doi:10.1128/JVI.02335-10.
9. Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, et al. (2011) Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 19: 691-699 doi:10.1016/j.str.2011.02.012.
10. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470 doi:10.1038/nature10373.
11. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, et al. (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 88: 10134-10137.
12. Barbas CF, Collet TA, Amberg W, Roben P, Binley JM, et al. (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230: 812-823.
13. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
14. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, et al. (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159 doi:10.1126/science.1061692.
15. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. (2009) Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15: 951-954 doi:10.1038/nm.1974.
16. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. Aids Res Hum Retrov 17: 1757-1765 doi:10.1089/08892220152741450.
17. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84: 1302-1313 doi:10.1128/JVI.01272-09.
18. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018.
19. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210 doi:10.1038/72318.
20. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78: 3155-3161.
21. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA, (2004) Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12: 193-204 doi:10.1016/j.str.2004.01.003.
22. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, et al. (2010) Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol 17: 955-961 doi:10.1038/nsmb.1861.
23. Kwong PD, Wyatt RT, Robinson JE, Sweet RW, Sodroski JG, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659 doi:10.1038/31405.
24. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, et al. (2009) A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83: 8451-8462 doi:10.1128/JVI.00685-09.
25. Wilson PC, de Bouteiller O, Liu Y, Potter K, Banchereau J, et al. (1998) Somatic hypermutation introduces insertions and deletions into immunoglobulin genes. J Exp Med 187: 59-70.
26. Wilson PC, Liu Y, Banchereau J, Capra JD, Pascual V, (1998) Amino acid insertions and deletions contribute to diversify the human Ig repertoire. Immunol Rev 162: 143-151.
27. Reason DC, Zhou J, (2006) Codon insertion and deletion functions as a somatic diversification mechanism in human antibody repertoires. Biol Direct 1 - doi:10.1186/1745-6150-1-24.
28. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312 doi:10.1038/nature01470.
29. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100: 4144-4149 doi:10.1073/pnas.0630530100.
30. Ivanov II, Schelonka RL, Zhuang Y, Gartland GL, Zemlin M, et al. (2005) Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol 174: 7773-7780.
31. Schelonka RL, Zemlin M, Kobayashi R, Ippolito GC, Zhuang Y, et al. (2008) Preferential use of DH reading frame 2 alters B cell development and antigen-specific antibody production. J Immunol 181: 8409-8415.
32. Vale AM, Tanner JM, Schelonka RL, Zhuang Y, Zemlin M, et al. (2010) The peritoneal cavity B-2 antibody repertoire appears to reflect many of the same selective pressures that shape the B-1a and B-1b repertoires. J Immunol 185: 6085-6095 doi:10.4049/jimmunol.1001423.
33. Schroeder HW, Wang JY, (1990) Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life. Proc Natl Acad Sci USA 87: 6146-6150.
34. Ippolito GC, Schelonka RL, Zemlin M, Ivanov II, Kobayashi R, et al. (2006) Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med 203: 1567-1578 doi:10.1084/jem.20052217.
35. Schelonka RL, Tanner J, Zhuang Y, Gartland GL, Zemlin M, et al. (2007) Categorical selection of the antibody repertoire in splenic B cells. Eur J Immunol 37: 1010-1021 doi:10.1002/eji.200636569.
36. Schroeder HW, Zemlin M, Khass M, Nguyen HH, Schelonka RL, (2010) Genetic control of DH reading frame and its effect on B-cell development and antigen-specifc antibody production. Crit Rev Immunol 30: 327-344.
37. Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, et al. (2011) High-resolution description of antibody heavy-chain repertoires in humans. PLoS ONE 6: e22365 doi:10.1371/journal.pone.0022365.
38. Aguilera I, Melero J, Nuñez-Roldan A, Sanchez B, (2001) Molecular structure of eight human autoreactive monoclonal antibodies. Immunology 102: 273-280.
39. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, et al. (2003) Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377 doi:10.1126/science.1086907.
40. Crouzier R, Martin T, Pasquali JL, (1995) Heavy chain variable region, light chain variable region, and heavy chain HCDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors. J Immunol 154: 4526-4535.
41. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908 doi:10.1126/science.1111781.
42. Wu Y-C, Kipling D, Leong HS, Martin V, Ademokun AA, et al. (2010) High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 116: 1070-1078 doi:10.1182/blood-2010-03-275859.
43. Zemlin M, Schelonka RL, Ippolito GC, Zemlin C, Zhuang Y, et al. (2008) Regulation of repertoire development through genetic control of DH reading frame preference. J Immunol 181: 8416-8424.
44. Ivanov I, Link J, Ippolito G, Schroeder HJ, (2002) The Antibodies. Capra JD, Zanetti M, editors CRC Press. p.
45. Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, et al. (2011) An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. MBio 2: e00345-10 doi:10.1128/mBio.00345-10.
46. Burton DR, (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706-713 doi:10.1038/nri891.
47. Douek DC, Kwong PD, Nabel GJ, (2006) The rational design of an AIDS vaccine. Cell 124: 677-681 doi:10.1016/j.cell.2006.02.005.
48. Walker LM, Burton DR, (2010) Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22: 358-366 doi:10.1016/j.coi.2010.02.012.
49. Burton DR, (2010) Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci USA 107: 17859-17860 doi:10.1073/pnas.1012923107.
50. van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, et al, (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17: 2257-2317 doi:10.1038/sj.leu.2403202.
51. Lefranc M-P, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucl Acids Res 37: D1006-12 doi:10.1093/nar/gkn838.
52. Brochet X, Lefranc M-P, Giudicelli V, (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucl Acids Res 36: W503-8 doi:10.1093/nar/gkn316.